Alkermes Plc (ALKS)

Apr 19, 2026

Alkermes (ALKS) nears 52-week high on increasing orexin receptor market interest - MSN

Apr 19, 2026

Apr 19, 2026

(ALKS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Apr 19, 2026

Apr 18, 2026

Avadel Stock Rises After Acquisition Offer By Alkermes - MSN

Apr 18, 2026

Apr 18, 2026

Alkermes plc stock (IE00B56GVS15): Is its neuroscience focus strong enough to drive steady upside? - AD HOC NEWS

Apr 18, 2026

Apr 17, 2026

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting - BioSpace

Apr 17, 2026

Apr 16, 2026

Wolfe Research initiates coverage of Alkermes (ALKS) with outperform recommendation - MSN

Apr 16, 2026

Apr 16, 2026

Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities - CSRwire

Apr 16, 2026

Apr 16, 2026

Alkermes (ALKS) Unveils Promising Data on Alixorexton for Narcol - GuruFocus

Apr 16, 2026

Apr 16, 2026

Alkermes to present narcolepsy drug data at neurology meeting - Investing.com

Apr 16, 2026

Apr 16, 2026

Alkermes to present narcolepsy drug data at neurology meeting By Investing.com - Investing.com Canada

Apr 16, 2026

Apr 16, 2026

Narcolepsy patients showed 13 weeks of gains in Alkermes study - Stock Titan

Apr 16, 2026

Apr 16, 2026

Robeco Institutional Asset Management B.V. Purchases 151,283 Shares of Alkermes plc $ALKS - MarketBeat

Apr 16, 2026

Apr 16, 2026

ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill

Apr 16, 2026

Apr 14, 2026

Alkermes (ALKS) Reveals Positive Findings on Lybalvi for Schizop - GuruFocus

Apr 14, 2026

Apr 14, 2026

Alkermes publishes 56-week study on Lybalvi negative symptoms By Investing.com - Investing.com Australia

Apr 14, 2026

Apr 14, 2026

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry - BioSpace

Apr 14, 2026

Apr 14, 2026

Alkermes publishes 56-week study on Lybalvi negative symptoms - Investing.com

Apr 14, 2026

Apr 14, 2026

Schizophrenia study tracks symptom gains for 56 weeks on LYBALVI - Stock Titan

Apr 14, 2026

Apr 13, 2026

Should Alkermes’ (ALKS) New Phase 3 Narcolepsy Program Reshape Its Sleep-Disorder Investment Narrative? - simplywall.st

Apr 13, 2026

Apr 13, 2026

Alkermes (ALKS) director Nancy Lurker exercises RSUs, netting 13,555 shares - Stock Titan

Apr 13, 2026

Apr 13, 2026

Tudor Investment Corp ET AL Takes Position in Alkermes plc $ALKS - MarketBeat

Apr 13, 2026

Apr 11, 2026

ALKS (Alkermes) Cash Receipts from Operating Activities - GuruFocus

Apr 11, 2026

Apr 10, 2026

Alkermes PLC (ALKS) Stock Down 4.5% but Still Overvalued -- GF S - GuruFocus

Apr 10, 2026

Apr 10, 2026

Alkermes PLC (ALKS) Stock Down 4.5% but Still Overvalued -- GF Score: 79/100 - GuruFocus

Apr 10, 2026

Apr 10, 2026

Will Alkermes plc benefit from government policyEarnings Growth Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

B of A Securities Raises Price Target for ALKS to $36 | ALKS Sto - GuruFocus

Apr 09, 2026

Apr 08, 2026

Market Fear: Is Alkermes plc stock showing strong momentum2026 PostEarnings & Capital Efficient Trading Techniques - baoquankhu1.vn

Apr 08, 2026

Apr 08, 2026

How (ALKS) Movements Inform Risk Allocation Models - Stock Traders Daily

Apr 08, 2026

Apr 07, 2026

Alkermes PLC (ALKS) Stock Price Down 4.08% on Apr 7 - GuruFocus

Apr 07, 2026

Apr 07, 2026

RBC Capital Adjusts Price Target on Alkermes Public to $44 From $45, Maintains Outperform Rating - marketscreener.com

Apr 07, 2026

Apr 06, 2026

Insider Sell Alert: David Gaffin Sells Shares of Alkermes PLC - GuruFocus

Apr 06, 2026

Apr 06, 2026

Alkermes (NASDAQ:ALKS) EVP Sells $70,315.38 in Stock - MarketBeat

Apr 06, 2026

Apr 06, 2026

Alkermes (ALKS) EVP David Gaffin sells 2,034 shares in 10b5-1 trade - Stock Titan

Apr 06, 2026

Apr 06, 2026

Alkermes (NASDAQ: ALKS) 2026 proxy outlines CEO change, $1.48B 2025 revenue and Avadel acquisition - Stock Titan

Apr 06, 2026

Apr 06, 2026

Alkermes plc (NASDAQ: ALKS) Form 144 lists affiliate sale amounts - Stock Titan

Apr 06, 2026

Apr 06, 2026

Is Alkermes (ALKS) Building a Durable Sleep-Disorder Franchise With Its Brilliance Phase 3 Bet? - simplywall.st

Apr 06, 2026

Apr 06, 2026

Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program - CSRwire

Apr 06, 2026

Apr 03, 2026

Alkermes Starts Phase 3 Program for Narcolepsy Drug Candidate Alixorexton - Sleep Review

Apr 03, 2026

Apr 02, 2026

Alkermes plc (ALKS) stock price, news, quote and history - Yahoo Finance UK

Apr 02, 2026

Apr 02, 2026

Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat

Apr 02, 2026

Apr 02, 2026

Alkermes stock hits 52-week high at $36.46 By Investing.com - Investing.com South Africa

Apr 02, 2026

Apr 02, 2026

Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN

Apr 02, 2026